Search


FDA and MHRA Move Away From Animal Testing: What the New Approach Methodologies (NAMs) Shift Means for Regulatory Affairs Professionals in 2026
The FDA NAMs roadmap for reducing animal testing is now over a year into implementation, and the Medicines and Healthcare products Regulatory Agency (MHRA) has published its own parallel guidance on non-animal methods. Together, these changes affect any sponsor preparing nonclinical safety data for an Investigational New Drug (IND) application, a Clinical Trial Authorisation (CTA), or a Marketing Authorisation (MA) in the US or UK. As of September 2026, developers who can jus
15 minutes ago9 min read



